RecruitingNCT07291141

A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis


Sponsor

Mattias Ekstedt

Enrollment

600 participants

Start Date

Dec 18, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals. A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability. The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk. Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories. The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares MRI and ultrasound scans to see which is better at detecting early-stage liver cancer (hepatocellular carcinoma, or HCC) in people who already have liver cirrhosis (scarring of the liver). **You may be eligible if...** - You are between 18 and 84 years old - You have liver cirrhosis diagnosed through standard methods (such as biopsy, imaging, or elastography) - You are able to give written consent **You may NOT be eligible if...** - You cannot have an MRI (e.g., due to metal implants, severe claustrophobia) - You are pregnant - You have primary sclerosing cholangitis, vascular liver disease, or congenital liver fibrosis - You have already been diagnosed with liver cancer (HCC) - You have had a liver transplant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Department of gastroenterology and hepatology, University hospital in Linköping

Linköping, Select A State Or Province, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07291141


Related Trials